Tvardi Therapeutics, Inc. (TVRD) stock
Close on Nov 12, 2026Market cap $15.41MP/E –Yield 0.00%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $15.41M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.84
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Net income
- -$26.06M
- EPS, diluted
- -$3.26
- Book value per share
- $0.89
- Diluted shares
- 9M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $1.34
- Open
- $1.30
- Day's range
- $1.15 – $1.30
- Volume
- 167,027
- Average volume (20 days)
- 379,804
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 1.12
- 52-week range
- $0.77 – $5.69
- RSI (14 days)
- 63.7
- Volatility (1 year)
- 130.0%
- Relative volume
- 0.27×
- WACC
- 10.5%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TVRD | S&P 500 | Difference | TVRD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +9.0% | -2.7% | +11.7 pts | ||
| 3 months | -34.7% | -1.7% | −33.0 pts | ||
| Year to date | -73.1% | +11.9% | −85.0 pts | ||
| 1 year | -72.8% | +12.0% | −84.7 pts | ||
| 3 years | -96.9% | +78.2% | −175.1 pts | -68.7% | +21.2% |
| 5 years | -99.8% | +73.2% | −173.0 pts | -71.2% | +11.6% |
| 10 years | -99.7% | +309.6% | −409.3 pts | -43.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tvardi Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
About Tvardi Therapeutics
Pharmaceutical Preparations
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral, small molecule therapeutics targeting Signal Transducer and Activator of Transcription 3 (STAT3). The firm develops treatments for inflammatory and proliferative diseases with significant unmet need driven by dysregulated STAT3 signaling. Its development pipeline centers on two investigational small molecules: TTI-101, a direct STAT3 inhibitor in clinical trials for hepatocellular carcinoma and idiopathic pulmonary fibrosis, and TTI-109, an oral phosphate prodrug engineered to enhance systemic delivery and tolerability. As a clinical-stage development enterprise without approved commercial products, the company does not currently sell directly to commercial end users or consumers.
Company profile, executives and historyTvardi Therapeutics stock: common questions
What is Tvardi Therapeutics's stock price?
TVRD closed at $1.16 on Nov 12, 2026, down 13.81% on the day. Over the past 52 weeks it traded between $0.77 and $5.69.
What is Tvardi Therapeutics's market cap?
Tvardi Therapeutics was worth $15.41M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TVRD's P/E ratio?
Tvardi Therapeutics lost money over fiscal 2025 (diluted EPS -$3.26), so it has no meaningful P/E ratio.
Does Tvardi Therapeutics pay a dividend?
No. Tvardi Therapeutics has not paid a cash dividend over the last twelve months.
When does Tvardi Therapeutics report earnings next?
Tvardi Therapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has TVRD stock performed over the past year?
Including dividends, TVRD returned -72.8% over the past year, against +12.0% for the S&P 500.
How many TVRD shares are sold short?
0M shares were sold short at the latest FINRA report, 2.66% of the float, or 2.5 days of average trading volume.
Who are Tvardi Therapeutics's competitors?
Companies most similar to Tvardi Therapeutics by business, industry and size include ALMS, ACRS, TRAW, HCWB, RANI.
See a number that looks wrong?